• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A process of preparing a serum protein composition for intravenous application or administration, in which process, starting from a human blood protein solution, a stabilized, universally applicable preparation or composition is prepared which contains dissolved in an aqueous isotonic solution, such proteins in which the ratio of globulins and albumins corresponds substantially to that of the native blood serum, in the following steps: (a) fractionation of human blood plasma upon removal of coagulation factors according to a process known per se recovering thereby precipitates and supernatants of different fractionation steps, (b) mixing and resolving of precipitates of different fractionation steps, preferably the COHN-fractions IV, III-1 and III-2), in which blood proteins, especially albumin and globulins, are preserved in a native form, said precipitates mixed and resolved in a chemically and physiologically adapted solvent, said solvent eventually containing also supernatants of the fractionation steps, (c) adjustment of the mixture to a content of 50-70% albumin and 30-50% globulin, related to the entire protein content, (d) stabilizing, purification and drawing off the preparation in a suitable manner.
    公开号:SU786854A3
    申请号:SU782572351
    申请日:1978-01-26
    公开日:1980-12-07
    发明作者:Радовитц Маркус
    申请人:Пласмеско Аг (Фирма)；
    IPC主号:
    专利说明:

    At -globulin fraction II I - I is treated further as follows. The precipitate P is immersed in citrate-phosphate buffer with a pH from 7.0 to 7.4, at a temperature of 15 ° C. 3% polyethylene glycol 4000 (MOAT) or 2.5% PE Y 6000 is added. After the reaction, which lasts from 30 minutes to 4 hours, the mixture is fed to a centrifuge. Get the supernatant fraction II1-1 {precipitate P). The supernatant Sj- is further processed and fractionated at pH 4.6, the amount of PE is about 5% at a temperature of -15 ° C). The HI fraction (Pg precipitate) is obtained, as well as the supernatant 5, which mainly contains. immune globulin. Globulin fractions II1-1 and III significantly enrich immununi with globulins IgG, IgA IgM In addition, it contains α-antitrypsin, α-haptoglobin, ceruloplasmin, trannoferrin and chemopexin. Fractions III-1 and W are not further processed. As a starting product, both fraction IV and M1-I and IP fractions are used. They are mixed in established ratios, with total proteins containing from 50 to 70% albumin or 50 to 30% globulin. It is also possible, by a corresponding increase in the addition of a portion of globulin or fractions J M -1 and IN, to increase the proportion of globulin igM and, IgA . Fractions IV, (And- and 1I cycneHSHp are in solution of common salt or in another suitable buffer solution, wt.%: Fraction IV30-80 Fraction III - I 0-70 Fraction) II0-70, and the total amount of proteins is 100%. The preparation on the basis of protein serum can be obtained only from any one of the fractions I and - I; III or obtain specific plasmid, moproteins from separate fractions in a stable, dissolved form as a preparation. The drug can be obtained from a mixture of the resulting final products of the Itl-I, 1.1 I and IV fractions. Substances mixed in certain ratios and suspended in a suitable buffer solution or in a solution of sodium chloride are pretreated. When pre-cleaning by adsorption on suitable adsorbents (aerosol bentonite or other silicon-containing complex compounds), the linden factors JL- and p-globulins are removed. After this, the product is filtered, dialyzed and set the desired concentration of the solution. To eliminate viruses, it is pasteurized by heating to 60 ° C for 10 hours. However, under these conditions, it is possible to denature whey proteins or else they are treated with propiolactone and ultraviolet rays. The method is illustrated by the following examples. Example 1. KZ00 l solution. salt (distilled water with 1.7% by weight of NaCl, which is obtained using 6.2 N. HCl with a pH of 4.6) is added 10 kp COHN fraction IV with the following protein analysis and suspended,% g Albumin55 X- - Globulin10. D -Globul and 8 P -Globulin15 y -Globulin-12 Fraction IV contains about 50% solids (protein, salt) and 50% wet residue (, residual ethanol). Next, add 5 kp CPM fraction II (-1 (subfraction) with the following analysis of solids, wt.%: Albumin 15 olw -Globulin2, d -Globulin13 (-Globulin17 / d -Globulin, 53 and 5 kp COHN subfraction IN-2 with the following analysis is suspended, - wt.%: Albumin .8 di -Globulin3 cC -Globulin9 p -Globulin25 Jr-Globulin55 The ratio of solid matter and the wet residue in all fractions is almost the same. 20 kp of the flag fraction is suspended in solution and mixed. the pH value is kept constant and equal to 4. b. Soluble substance, having in solution, dissolves. Maked with an insoluble substance gives turbidity to the solution and is about -12% with respect to the total amount of solid constituents. Among the insoluble substances are, in particular, denatured globulins, including lipoproteins, which are at further steps of the method are not needed. The latter are removed by centrifugation. The liquid left behind is slightly turbid and yellowish in color. Add 0.2 NaOH, adjust pH to 7.4. Pure colloidal silicon salt is added to the solution to a concentration of 5 wt.% And everything is stirred. The liquid is warmed to (about 1 minute per minute) and the pH is kept constant. After reaching a temperature of 45 ° C, the liquid is stirred for 4 hours. During the process, the long-lasting proteins combine with silicic acid and form a precipitate, which is removed by centrifugation. The liquid remaining after centrifugation is clarified by passing it through an activated carbon filter. Thereafter, the filtrate becomes amber transparent. The liquid is then concentrated to 25% with respect to the initial volume using the diaconcentration method (millipores — cassette system, membrane — 10,000 Dalton pore size). Thereafter, the protein concentration in the solution is 3.4-4.5% by weight. The analysis shows that, due to the diaconcentration stage, all fractions constituting blood with a molecular weight less than 10,000 are removed from the concentrate. They include fractions that are undesirable for preservation, for example, oligopeptides with a vasoactive effect. After that, for the final removal of impurities, as well as electrolytic dialysis, the treatment is carried out with a three-fold solution, 0.9% NaCB. Dialysis wire in the same apparatus with the same membranes, which are used during concentration. Subsequently, the concentration is completed by establishing a protein concentration of 6-10%. After that, using the NaC8 solution, the physiological conditions of isotony inherent in human blood are established, and the total protein concentration becomes 5%. The analysis of the proteins obtained in Example 1 showed the following values, mg: (content in 100 ml) Protein 5.000 Albumin 2.925. 500 IgA380 IgM.285 The resulting solution is additionally filtered through sterilizing filters. Sterile filtration occurs due to membrane filters. Thereafter, the preparation is ready for intravenous injection. Example 2. The solution of the brine solution, as in example 1, is dissolved, kp: 7.5 COHN fraction IV 4 COHN fraction III-I 8 COHN fractions tII The composition of these corresponds to example 1. The fractions are mixed with the solvent, the pH value is maintained 4.6 . 60 g per liter of aerosil is added to the solution and the pH value is set at 7.6 and mixed at a temperature of 47 ° C for 4 hours, after which the solution is cooled to 18 and filtered hydraulically. Hydraulic filtration is carried out in in-line filters, type CHF-S. Super Cet of 8% concentration per total amount of filtrate is used as filtering agent. Kieselguhr Celite 545 in 5% concentration can also be used as a filtering agent. Example 3. After purification, the solutions are separated and subjected to deaconcentration treatment, as in Example 1. They can, if desired, be treated to obtain the final concentrate according to the method described in Example 1, and after that, optionally, be combined into any composition. Example 4. In a 200 l phosphate-citrate buffer solution (0.66 mol phosphate citrate), 10 kp of fraction III is dissolved within 3 hours. The pH is adjusted to 7.5 and, after subsequent dilution, in 300 l mixed with the aforementioned buffer solution while adding 100 g / l of aerosil / bentonite (2: 1) for 4 hours at-45 s. After cooling to 10 ° C, the suspension is filtered on a bulk filter through a filtrate, for which kiesel celite .545 is used, the amount of which per 1 m of filter surface is 1.0 kg, and the filter capacity is 50 l / m h. Filtration occurs as diaconcentration in examples 1-3. The solution of the final concentrate contains 5% protein. The average composition of the following, mg: Protein5000 Albumin About 1SOO-2000 Globulin3.000-3200 Ig f About 1.450 IgA About 700 IgM About 500 Example 5. COHN fractions 1-1II and IV-I with an ethanol concentration of 40% and with pH value 5 8 are highlighted in steps. The fraction IV-I should be understood as a fraction identical to fraction IV. The precipitate is isolated 20 kg of the precipitate, as in example 1, immersed in 300 liters of solvent and then treated. Example 6. Fractionation of human plasma was carried out using rivanol (2-ethoxy-6,9-digilino-acidinyl acetate), and precipitates II, III and IV were precipitated. These precipitates can be treated with the proposed method before the preparation of the protein whey preparation. 10 kp of each sediment, i.e. together it is 30 kp, added to 300 liters of solvent, as in example 1. Further processing is carried out as in example 1. Example 7. In 200 liters of saline solution (distilled water with 1.7 weight .% NaCB, in which the pH value with the help of 0.2 N. HC is set at 4, b and which is called solvent below) 6.0 kp COHN fraction IV is added with the following analysis of the protein components and suspended, by weight,%:
    Albumin53
    оС, -Globulina 11
    j
    H -Globulin 8
    -Globulin 14
    G1 maglobulin 14
    Then 4.0 kp COHN of IN subfractions are added with the following analysis of protein components, wt%:
    Albumin7
    (JL ;, -Globulin 3
    .d -Globulin9
    R -Globulin 26
    Gammaglobulin 56
    The ratio of residual moisture (, residual ethanol) and solids (proteins, salts) is about 1: 1.
    10 kp of the wet fraction is suspended in a solvent and stirred. The pH value is kept constant at 4, 6. The following stages proceed as described in example 1 (centrifugation; treatment with krenic acid, filtration on active carbon, concentration by dialysis).
    Per 100 ml of solution at 5.000 mg of the established protein content
    about 37% of shushbumin, respectively, 1.850 mg, about 63% of globulins, respectively, 3.150 mg, immune, globulin, mg: IgG are obtained. About 1,450 IgA. About 700 IgM. About 500. The proposed method allows to obtain a serum-based drug with an increased immunoglobulin content.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining a protein-based whey preparation by fractionation of plasma followed by adsorption, purification and sterilization, characterized in that, in order to increase the immunoglobulin content, the plasma is freed from coagulation products, fractionated according to the Kona method, fractions obtained after fractionation III III-I and 111-11, the latter are mixed with the fraction. IV and suspend the mixture in saline.
    Sources taken into account during examination i
    1, W.Stephan - Vox Sanguim, 442457, 1975.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU786854A3|1980-12-07|Method of producing protein serum-based preparate
    US4322275A|1982-03-30|Fractionation of protein mixtures
    JP3094167B2|2000-10-03|Purification method of immune serum globulin
    US4351710A|1982-09-28|Fractionation of protein mixtures
    EP0503991A1|1992-09-16|Process for preparing a highly purified standardized concentrate of human von Willebrand factor on industrial scale, appropriate for therapeutic use
    US5219999A|1993-06-15|Immunoglobulin g and process for the production thereof
    US4081431A|1978-03-28|Blood fractionation
    JP2002517516A|2002-06-18|Methods for producing immunoglobulins and other immunoglobulin products for intravenous administration
    FR2492270A2|1982-04-23|ELECTRODIALYSIS APPARATUS AND METHOD FOR FRACTIONING PROTEIN MIXTURES
    US4386068A|1983-05-31|Antihemophilic factor concentrate and method for preparation
    SE447790B|1986-12-15|PROCEDURE FOR THE PREPARATION OF AN INTRAVENOST ADMINISTRATIVE ANTIBODY-CONTAINING IMMUNGLOBULIN PREPARATION
    GB2179947A|1987-03-18|Process for the extraction of proteins from milk
    EP0512883B1|1997-08-06|Process for preparing a concentrate of blood coagulation factor XI with high specific activity, appropriate for therapeutic use
    US3429867A|1969-02-25|Serum substantially free from gamma globulin and method of preparing same
    US4476109A|1984-10-09|Method of preparing gamma globulin suitable for intravenous administration
    EP1037923A1|2000-09-27|Method for preparing by filtration a virally secure factor viii solution
    PL165402B1|1994-12-30|Method of obtaining purifield albumin solutions
    US4197238A|1980-04-08|Method of preparation of human albumin using polyethylene glycol
    US4302445A|1981-11-24|Method for concentrating and purifying antihemophilic factor or factor VIII
    DK151610B|1987-12-21|PROCEDURE FOR THE MANUFACTURE OF HUMAN IMMUNOGLOBULIN PREPARATIONS WITH REDUCED COMPLEMENT ACTIVITY AND GOOD ANTISTOFACTIVITY
    JP3106509B2|2000-11-06|Method for producing anti-human lymphocyte antibody
    JPH08787B2|1996-01-10|Method for producing composition containing gamma globulin
    DK141523B|1980-04-14|PROCEDURE FOR INSULATING ALBUMIN FROM BLOOD BLOOD PRODUCTS AND PLACENT BLOOD
    RU2189833C2|2002-09-27|Method of immunoglobulin preparation preparing
    JP2003159094A|2003-06-03|Method for aseptically producing yolk antibody
    同族专利:
    公开号 | 公开日
    DK35478A|1978-07-27|
    EG13119A|1981-03-31|
    DD133632A5|1979-01-17|
    FI63673C|1983-08-10|
    FI780212A|1978-07-27|
    YU16578A|1983-10-31|
    ES466385A1|1978-10-01|
    IL53856A|1981-03-31|
    HU182554B|1984-02-28|
    DE2801123A1|1978-07-27|
    BE863278A|1978-05-16|
    AU3260078A|1979-07-26|
    FR2378524A1|1978-08-25|
    NL7800606A|1978-07-28|
    IN147713B|1980-06-07|
    JPS5396315A|1978-08-23|
    ZA78295B|1978-12-27|
    IE46304B1|1983-04-20|
    IE780088L|1978-07-26|
    DE2801123C2|1986-01-02|
    GB1597204A|1981-09-03|
    JPS6241211B2|1987-09-02|
    PL204214A1|1978-09-25|
    PL124730B1|1983-02-28|
    SE447204B|1986-11-03|
    FI63673B|1983-04-29|
    DK152334C|1988-07-25|
    DK152334B|1988-02-22|
    US4216205A|1980-08-05|
    FR2378524B1|1983-02-04|
    AR220328A1|1980-10-31|
    SE7800443L|1978-07-27|
    AU522413B2|1982-06-03|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1207477A|1969-04-29|1970-10-07|Ts I Gematologii I Perelivania|Plasma proteins solution|
    US3770631A|1971-06-29|1973-11-06|Baxter Laboratories Inc|Clarification of blood serum and plasma|
    JPS5620287B2|1972-06-19|1981-05-13|
    US4073886A|1973-01-30|1978-02-14|Baxter Travenol Laboratories, Inc.|Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene|
    US3850903A|1973-06-21|1974-11-26|S Mankarious|Plasma volume expander prepared from cohn iv precipitate using block copolymers of ethylene oxide and polyoxypropylene|
    DE2459291C3|1974-12-14|1981-06-04|Biotest-Serum-Institut Gmbh, 6000 Frankfurt|Process for the production of a concentrate containing antihemophilic globulin A in addition to a prothrombin complex and a solution of storage-stable serum proteins|US4321192A|1980-01-10|1982-03-23|Ionics Incorporated|Fractionation of protein mixtures by salt addition followed by dialysis treatment|
    FR2492269B2|1980-01-10|1984-04-27|Ionics|
    US4322275A|1980-01-10|1982-03-30|Ionics Incorporated|Fractionation of protein mixtures|
    US4351710A|1980-01-10|1982-09-28|Ionics, Incorporated|Fractionation of protein mixtures|
    WO1982002841A1|1981-02-18|1982-09-02|University Patents Inc|Precipitation of proteins|
    US4452893A|1981-08-03|1984-06-05|Cutter Laboratories, Inc.|Cell growth medium supplement|
    US4391801A|1981-10-29|1983-07-05|Cutter Laboratories, Inc.|Plasma protein fraction substantially free of acetate ions|
    US4439421A|1982-08-30|1984-03-27|Baxter Travenol Laboratories, Inc.|Stabilized gamma globulin concentrate|
    DE3245591C2|1982-12-09|1986-11-06|Schott Glaswerke, 6500 Mainz|Process for the fractional separation of mixtures of substances with membranes|
    US4486282A|1983-02-22|1984-12-04|University Patents, Inc.|Precipitation of proteins from salt-containing proteinaceous fluids employing a desalting treatment, and use thereof in selective plasmapheresis|
    DE3344656A1|1983-12-09|1985-06-13|Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München|METHOD FOR PRODUCING A SERUM PROTEIN SOLUTION|
    US5420250A|1990-08-06|1995-05-30|Fibrin Corporation|Phase transfer process for producing native plasma protein concentrates|
    CA2066374C|1991-04-19|2002-01-29|Paul E. Segall|Solution for perfusing primates|
    CN1055095C|1992-12-11|2000-08-02|上海莱士血制品有限公司|Purification of white protein|
    US5945272A|1993-06-04|1999-08-31|Biotime, Incorporated|Plasma expanders and blood substitutes|
    US6627393B2|1993-06-04|2003-09-30|Biotime, Inc.|Solutions for use as plasma expanders and substitutes|
    US6680305B1|1993-06-04|2004-01-20|Biotime, Inc.|Physiologically acceptable aqueous solutions and methods for their use|
    US6218099B1|1994-06-03|2001-04-17|Biotime, Inc.|Methods and compositions for use in perfusion applications|
    PT701455E|1993-06-04|2001-09-27|Biotime Inc|PLASMA SIMPLE SOLUTION|
    US6300322B1|1993-06-04|2001-10-09|Biotime, Inc.|Plasma-like solution|
    US6589223B1|1999-02-03|2003-07-08|Biotime, Inc.|Method and compositions for use in perfusion applications|
    US6441144B1|1999-05-20|2002-08-27|Alpha Therapeutic Corporation|Method for repairing dual virally inactivated immune globulin for intravenous administration|
    US6596262B2|2001-02-15|2003-07-22|Aeropharm Technology Incorporated|Modulated release particles for aerosol delivery|
    US6806355B2|2001-08-14|2004-10-19|Statens Serum Institut|Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product|
    CA2742994A1|2008-11-12|2010-05-20|Baxter International Inc.|Purification of butyrylcholinesterase using membrane adsorption|
    US8772462B2|2010-05-26|2014-07-08|Baxter International Inc.|Removal of serine proteases by treatment with finely divided silicon dioxide|
    AU2010202125B1|2010-05-26|2010-09-02|Takeda Pharmaceutical Company Limited|A method to produce an immunoglobulin preparation with improved yield|
    US8796430B2|2010-05-26|2014-08-05|Baxter International Inc.|Method to produce an immunoglobulin preparation with improved yield|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH93477|1977-01-26|
    AT0185977A|AT367297B|1977-03-17|1977-03-17|METHOD FOR PRODUCING A SERUM PROTEIN PR [PARATE|
    [返回顶部]